RxDoctor Payments Data

Nicole Wells

Family · Fredericksburg, VANPI 1598419368

Payments from drug & device makers

$10,042in general payments, 2019–2025

Across 628 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Lilly USA, LLC$999
  • AbbVie$933
  • Amgen$655
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$9,94299%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,042 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$47,296
Medicare patients
272
Services billed
639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$22,057
FarxigaDapagliflozin Propanediol17$15,095
Atorvastatin Calcium119$1,270
Prasugrel Hcl12$888
Ezetimibe27$778
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav96$755
ValacyclovirValacyclovir Hcl14$735
Gabapentin40$733
Levothyroxine Sodium43$592
Omeprazole25$532
Albuterol Sulfate HfaAlbuterol Sulfate35$403
Methylprednisolone73$378
Duloxetine Hcl13$368
Lisinopril45$360
Metformin Hcl50$349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$114$22,05724 claims
AstraZenecaFarxiga$1,120$15,09517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →